Elutia (ELUT) Competitors $4.16 -0.22 (-5.02%) (As of 11:56 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ELUT vs. CRVS, ABVX, ATXS, ORGO, IGMS, SANA, GLUE, GHRS, PRTC, and PROKShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Corvus Pharmaceuticals (CRVS), ABIVAX Société Anonyme (ABVX), Astria Therapeutics (ATXS), Organogenesis (ORGO), IGM Biosciences (IGMS), Sana Biotechnology (SANA), Monte Rosa Therapeutics (GLUE), GH Research (GHRS), PureTech Health (PRTC), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Corvus Pharmaceuticals ABIVAX Société Anonyme Astria Therapeutics Organogenesis IGM Biosciences Sana Biotechnology Monte Rosa Therapeutics GH Research PureTech Health ProKidney Corvus Pharmaceuticals (NASDAQ:CRVS) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk. Do analysts rate CRVS or ELUT? Corvus Pharmaceuticals currently has a consensus target price of $12.83, suggesting a potential upside of 47.51%. Elutia has a consensus target price of $10.00, suggesting a potential upside of 140.38%. Given Elutia's higher probable upside, analysts clearly believe Elutia is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CRVS or ELUT? Corvus Pharmaceuticals received 279 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 61.75% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCorvus PharmaceuticalsOutperform Votes28961.75% Underperform Votes17938.25% ElutiaOutperform Votes10100.00% Underperform VotesNo Votes Is CRVS or ELUT more profitable? Corvus Pharmaceuticals has a net margin of 0.00% compared to Elutia's net margin of -218.72%. Elutia's return on equity of 0.00% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -70.71% -45.90% Elutia -218.72%N/A -142.61% Does the media favor CRVS or ELUT? In the previous week, Elutia had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 9 mentions for Elutia and 7 mentions for Corvus Pharmaceuticals. Elutia's average media sentiment score of 0.36 beat Corvus Pharmaceuticals' score of 0.15 indicating that Elutia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Elutia 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in CRVS or ELUT? 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 40.8% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher valuation and earnings, CRVS or ELUT? Corvus Pharmaceuticals has higher earnings, but lower revenue than Elutia. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$27.03M-$0.93-9.35Elutia$24.75M5.72-$37.66M-$2.61-1.59 Which has more risk and volatility, CRVS or ELUT? Corvus Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. SummaryCorvus Pharmaceuticals and Elutia tied by winning 9 of the 18 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$141.69M$2.98B$5.09B$8.81BDividend YieldN/A1.91%5.04%4.07%P/E Ratio-1.5918.9994.6014.18Price / Sales5.72286.511,217.5288.10Price / CashN/A169.3839.4936.27Price / Book-3.534.416.956.35Net Income-$37.66M-$41.63M$118.83M$225.71M7 Day Performance8.62%-4.44%-1.52%-0.32%1 Month Performance24.18%-6.19%-3.39%1.76%1 Year Performance155.21%26.61%32.17%27.70% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia2.7107 of 5 stars$4.16-5.0%$10.00+140.4%+170.4%$141.69M$24.75M-1.59180Gap DownCRVSCorvus Pharmaceuticals2.7832 of 5 stars$8.70+5.6%$12.83+47.5%+449.3%$559.06MN/A-8.8630Analyst RevisionABVXABIVAX Société Anonyme3.0118 of 5 stars$8.75-1.2%$39.80+354.9%-19.6%$553.79MN/A0.0061ATXSAstria Therapeutics1.7093 of 5 stars$9.74+1.7%$25.60+162.8%+110.5%$549.63MN/A0.0030Analyst RevisionORGOOrganogenesis4.1178 of 5 stars$4.07+2.5%$5.33+31.0%+51.5%$539.60M$433.14M-66.17950Analyst RevisionIGMSIGM Biosciences4.7096 of 5 stars$9.07-7.2%$16.13+77.8%+63.3%$539.30M$2.13M-2.47190SANASana Biotechnology2.2306 of 5 stars$2.40-5.1%$13.50+462.5%-41.2%$535.85MN/A-1.69328GLUEMonte Rosa Therapeutics2.9694 of 5 stars$8.72+4.3%$16.00+83.5%+157.2%$535.76MN/A0.0090GHRSGH Research1.8331 of 5 stars$10.10-7.8%$35.67+253.1%+77.2%$525.50MN/A-13.6210Analyst ForecastNews CoveragePRTCPureTech Health2.2392 of 5 stars$21.81+0.5%$45.00+106.3%+0.9%$522.13M$3.33M0.00100Analyst RevisionNews CoveragePositive NewsPROKProKidney2.6021 of 5 stars$1.78+7.9%$4.50+152.7%-6.3%$515.93MN/A0.003News Coverage Related Companies and Tools Related Companies CRVS Competitors ABVX Competitors ATXS Competitors ORGO Competitors IGMS Competitors SANA Competitors GLUE Competitors GHRS Competitors PRTC Competitors PROK Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELUT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELUT Stock Alerts